Oramed Pharmaceuticals Dividends
| ORMP Stock | USD 3.61 0.11 3.14% |
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | -420.62 | -441.65 |
Oramed |
A short history of 1 dividends for Oramed Pharmaceuticals means consistency signals are still forming. Its latest recorded payout was 0.25 per share.
Expected Annual Dividend Income Per Share
Dividend payments represent a portion of Oramed Pharmaceuticals' earnings that management elects to return to shareholders, which is why expected dividend income matters for investors building an income-oriented thesis around Oramed Pharmaceuticals. Current scenario modeling points to about $0.08 in annual dividend income per share. There is only one recorded dividend event in the current history set, which limits how much confidence investors can place in pattern-based payout conclusions.
$0.08 |
Forward Year
Estimated dividend income per share for Oramed Pharmaceuticals after adjusting for ongoing price variability
Dividend Payment History
Past dividend distributions for Oramed Pharmaceuticals deserve attention because the chronology of declaration, record, ex-dividend, and payment dates determines who actually qualifies for the cash payout. There is only one recorded dividend event in the current history set, which limits how much confidence investors can place in pattern-based payout conclusions. Investors usually want to know whether the payout cadence has looked deliberate enough to support future expectations.
Dividends Overview and Assumptions
This block organizes Oramed Pharmaceuticals dividend cadence and payout stability for income-focused review. The most recent distribution was $0.25 on January 26, 2026.
Data shown for Oramed Pharmaceuticals is aggregated from periodic company reporting and market reference feeds and normalized across reporting formats. Source publication cadence can introduce delays.
This content is curated and reviewed by:
Rifka Kats - Member of Macroaxis Editorial Board Quarterly Earnings Growth 0.409 | Earnings Share 1 | Revenue Per Share | Quarterly Revenue Growth -1.00 | Return On Assets |
Investors evaluate Oramed Pharmaceuticals using market value and book value, each describing different facets of the business. Oramed Pharmaceuticals' market capitalization is 143.85 M. A P/B ratio of 0.69 suggests Oramed Pharmaceuticals trades near or below book value. Enterprise value stands at 5.48 M. Intrinsic value reflects what Oramed Pharmaceuticals' fundamentals imply about worth, which may differ from both the trading price and the book figure. Analytical frameworks help reconcile those views.
It is useful to distinguish Oramed Pharmaceuticals' value from its trading price, which are computed with different methods. For Oramed Pharmaceuticals, key inputs include a P/B ratio of 0.69, a profit margin of 21.93%, and ROE of 24.48%. The actual Oramed Pharmaceuticals transaction price is determined by real-time order flow on the exchange.